Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could ...

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved ...

Sino-American biopharma Ascentage Pharma has announced that olverembatinib has been granted Breakthrough Therapy Designation ...

US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025 may bring even more ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.

Ascentage Pharma Group International’s (NASDAQ:AAPG – Get Free Report) quiet period is set to expire on Wednesday, March 5th. Ascentage Pharma Group International had issued 7,325,000 shares in its ...

Ascentage Pharma (AAPG) announced that its drug, olverembatinib, has been granted a Breakthrough Therapy Designation by the Center for Drug ...

Ascentage Pharma’s olverembatinib gets China NMPA’s BTD to treat Philadelphia chromosome-positive acute lymphoblastic leukemia: Rockville Friday, March 7, 2025, 11:00 Hrs [IST ...

Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the ...

The quiet period for Ascentage Pharma Group International (NASDAQ:AAPG) is scheduled to conclude on March 5th.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ROCKVILLE, Md. and SUZHOU, China, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced today that the underwriters of its underwritten U.S. initial public ...